Key result
4-Phenyl-3-furoxancarbonitrile donates nitric oxide to induce vasodilation and inhibit platelet aggregation in rats.
4-Phenyl-3-furoxancarbonitrile is a promising nitric oxide donor with potent vasodilatory and antiplatelet effects in preclinical models.
Answers are grounded in this paper and cite their sources.
Should not change practice; leaves open translation of furoxan NO donors to human cardiovascular trials.
4-Phenyl-3-furoxancarbonitrile (2) affords nitric oxide under the action of thiol cofactors. Two principal products were isolated in the reaction with thiophenol: the phenylcyanoglyoxime (6) and 5-amino-3-phenyl-4-(phenylthio)isoxazole (7). Mechanisms which could account for the formation of these two products are discussed. Compound 2 is an efficient activator of the rat lung soluble guanylate cyclase, displays high vasodilatory activity on strips of rat thoracic aorta precontracted with noradrenaline, and is a potent inhibitor of platelet aggregation.
No takes yet. Share an insight, caveat, or question.
Medana et al. (1994) studied this question. 4-Phenyl-3-furoxancarbonitrile was evaluated on Guanylate cyclase activation, vasodilatory activity, and platelet aggregation inhibition. 4-Phenyl-3-furoxancarbonitrile acts as a nitric oxide donor, efficiently activating soluble guanylate cyclase, inducing vasodilation in rat aorta, and inhibiting platelet aggregation.
Synapse has enriched 10 related papers. Consider them for comparative context: